Attental has been proven in a randomized, double-blind, placebo controlled clinical trial to better overall motor performance and improve reading and spelling in children. The clinical trial demonstrated a significant improvement in the Conners’s Teaching Rating Scale-L (CTRS-L) of 59 items describing different aspects of child behavior, as well as in the Child Behavior Checklist (CBCL) – standard evaluation methods for ADHD.
Joos Horsten, executive chairman and CEO of Rhei, said: “Rhei will utilize its experience in pharmaceutical marketing and its network of contacts, particularly within the pediatric community, to bring this important natural remedy to the Asian market.”